Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ne-3413
- Development stage
- Preclinical
- Lead developer
- BioVie
- Modality
- Small Molecules
01
Overview
NE-3413 is a small molecule drug initially developed by NeurMedix for the treatment of nervous system diseases, with its current active indication being encephalitis. As of 2025, it has reached preclinical development. The detailed mechanism of action, molecular targets, and pathway involvement remain undisclosed or unreported in the available scientific and regulatory literature. NE-3413 is part of a portfolio of neuroinflammation-focused compounds acquired by BioVie from NeurMedix, Inc. No details on route of administration, formulation, or specific biochemical properties are published.
- Other names
- NE3413NE-3413NE 3413
Beyond the preview
Go deeper on ne-3413.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ne-3413.